NDA 205108 · Azurity
Sotylize
Sotalol Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Jan 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Oct 22, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
57
14 Phase 3, 9 recruiting
FAERS reports
2,530
2,120 serious, 255 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LIFE-THREATENING PROARRHYTHMIA To minimize the risk of drug-induced arrhythmia, initiate or re-initiate oral sotalol in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring. Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation. If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug. Calculate creatinine clearance to determine appropriate dosing [see Dosage and Administration (2.5) ] . WARNING: LIFE-THREATENING PROARRHYTHMIA See full prescribing information for complete boxed warning. Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation. If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug. Initiate or...
What it is approved for
From the label in effect Jan 24, 2024.
SOTYLIZE is an antiarrhythmic indicated for: The treatment of life-threatening ventricular arrhythmias ( 1.1 ) The maintenance of normal sinus rhythm in patients with highly symptomatic atrial fibrillation/flutter (AFIB/AFL) ( 1.2 ) Limitations of Use SOTYLIZE has not been shown to enhance survival in patients with life threatening ventricular arrhythmias ( 1.1 ) Avoid use in patients with minimally symptomatic or easily reversible AFIB/AFL ( 1.2 ) 1.1 Life-Threatening Ventricular Arrhythmia SOTYLIZE is indicated for the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia. Limitation of Use SOTYLIZE has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias. 1.2 Delay in Recurrence of Atrial Fibrillation/Atrial Flutter (AFIB/AFL) SOTYLIZE is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with highly symptomatic AFIB/AFL who are currently in sinus rhythm. Limitation of Use Because sotalol can cause life-threatening ventricular arrhythmias, reserve its use for patients in whom AFIB/AFL is highly symptomatic. Patients with paroxysmal AFIB that is easily reversed (by Valsalva maneuver, for example) should usually not be given SOTYLIZE .
Mechanism: Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. The two isomers of sotalol have similar Class III antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-blocking activity. The beta-blocking effect of sotalol is non-cardioselective, half maximal at an oral dose of about 80 mg/day and maximal at doses between 320 and 640 mg/day. Sotalol does not have partial agonist or membrane stabilizing activity. Although significant...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SOTYLIZE · SOTALOL HYDROCHLORIDE 5MG/ML (5MG/ML) · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sotalol" as an intervention, any sponsor and status, largest first.
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
- Kansai Plus Atrial Fibrillation TrialPivotal-lookingCompleted
Kyoto University, Graduate School of MedicineAcademic, hospital or other
NCT01477983 · 2,113 participants · Start Nov 2011 · Primary completion Jul 2017
Drug: Antiarrhythmic drug (AAD); Control and 2 more · For: Atrial Fibrillation
Sites: Kyoto, Japan
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00773201 · 997 participants · Start Feb 2008 · Primary completion Mar 2012
Drug: Sotalol 80 mg · For: Healthy Volunteers
Sites: Paris, France
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial FibrillationPivotal-lookingRecruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT07405671 · 988 participants (planned) · Start Sep 2026 · Primary completion Dec 2029
Drug: flecainide; Sotalol or Amiodarone · For: Atrial Fibrillation (AF); Coronary Artery Disease
Sites: Aalst, Belgium; Bonheiden, Belgium; Bruges, Belgium · 14 sites in all
- Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus RhythmPivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00007605 · 706 participants (planned) · Start Apr 1998 · Primary completion Oct 2002
Drug: Amiodarone; Sotalol · For: Atrial Fibrillation; Cerebrovascular Accident; Death, Sudden
Sites: Tucson, Arizona; No. Little Rock, Arkansas; Fresno, California · 28 sites in all
- Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00035451 · 658 participants · Start Feb 2001 · Primary completion Jun 2003
Drug: Azimilide Dihydrochloride; Placebo and 1 more · For: Atrial Fibrillation
Sites: Brussels, Belgium; Yvoir, Belgium; Aix-en-Provence, France · 129 sites in all
- Antiarrhythmic Drugs Assessment in Preventing Atrial FibrillationPivotal-lookingStatus unknown
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT02145546 · 600 participants (planned) · Start May 2014 · Primary completion May 2017
Drug: Amiodarone; Propafenone and 1 more · For: Atrial Fibrillation
Sites: Shanghai, China
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial FibrillationPivotal-lookingRecruiting
Samsung Medical CenterAcademic, hospital or other
NCT07447297 · 520 participants (planned) · Start Jan 2, 2024 · Primary completion Dec 15, 2027
Drug: early rhythm control group · For: Atrial Fibrillation (AF); Diseases of the Circulatory System; Atrial Flutter
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- atrial fibrillation171
- electrocardiogram qt prolonged148
- drug ineffective144
- hypotension123
- dyspnoea117
- bradycardia112
- dizziness110
- drug interaction99
- nausea93
- fatigue92
- fall86
- acute kidney injury72
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 31 |
| 2006 | 127 |
| 2007 | 234 |
| 2008 | 30 |
| 2009 | 123 |
| 2010 | 30 |
| 2011 | 79 |
| 2012 | 107 |
| 2013 | 57 |
| 2014 | 66 |
| 2015 | 55 |
| 2016 | 76 |
| 2017 | 96 |
| 2018 | 126 |
| 2019 | 147 |
| 2020 | 110 |
| 2021 | 95 |
| 2022 | 140 |
| 2023 | 151 |
| 2024 | 195 |
| 2025 | 253 |
| 2026 | 156 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sotylize (Sotalol HCl)
2024 spending
$52K
Beneficiaries
n/a
35 claims
Per beneficiary
n/a
$2.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $28,367 |
| 2021 | $56,705 |
| 2022 | $44,792 |
| 2023 | $17,572 |
| 2024 | $52,481 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment for beta-blocker poisoning: a systematic review.
Rotella JA, Greene SL, Koutsogiannis Z, et al. · Clin Toxicol (Phila) 2020 · Systematic Review
- Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.
Sapp JL, Tang ASL, Parkash R, et al. · N Engl J Med 2025 · Clinical Trial, Phase IV, Comparative Study
- Atrial fibrillation (acute onset).
Lip GY, Apostolakis S · BMJ Clin Evid 2014 · Systematic Review
- Atrial fibrillation (acute onset).
Lip GY, Watson T · BMJ Clin Evid 2008 · Systematic Review
- External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.
Kukendrarajah K, Ahmad M, Carrington M, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Atrial fibrillation (acute onset).
Lip GY, Apostolakis S · BMJ Clin Evid 2011 · Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.